UPDATE: Ladenburg Thalmann Downgrades AMAG Pharmaceuticals; Removes PT

According to a research report published this morning, Ladenburg Thalmann has downgraded AMAG Pharmaceuticals

from Buy to Neutral and removed its $19 PT. Ladenburg Thalmann commented in the report, "Our prior AMAG rating had been partially justified by expectations for a potential acquisition. In our view the appointment of a CEO indicates the probability of an acquisition in the relatively near term has been reduced significantly. As a standalone company we believe it will take time and good execution for AMAG to create value for shareholders." AMAG Pharmaceuticals is currently trading at $14.20.